Finance

Lists
RAPP:NASDAQ
Rapport Therapeutics Inc
$26.15
+1.16%
(+0.30) 1D
$26.25
+0.40% (+0.10)
After hours
Closed: Nov 13, 4:00:00 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for RAPP...
Open
$25.85
High
$26.29
Low
$25.11
Mkt. cap
1.55B
Avg. vol.
1.18M
Volume
316.12K
52-wk high
$52.93
52-wk low
$22.06
EPS
-$3.17
Shares outstanding
59.28M
No. of employees
84
Open
$25.85
High
$26.29
Low
$25.11
Mkt. cap
1.55B
Avg. vol.
1.18M
Volume
316.12K
52-wk high
$52.93
52-wk low
$22.06
EPS
-$3.17
Shares outstanding
59.28M
No. of employees
84
News stories
From web sources and news partners
About Rapport Therapeutics Inc
CEO-
Employees84
Founded2022
HeadquartersBoston, Massachusetts, United States
SectorHealth Care
IndustryPharmaceutical industry
Analyst ratings
Based on 14 analysts giving stock ratings to RAPP in the past 3 months
Strong buy
Buy
14
Hold
0
Sell
0
12-month forecast
Based on 14 Wall Street analysts offering 12 month price targets for RAPP in the last 3 months.
Highest
Current $26.15
$91.00 (+247.99%)
Average
$68.00 (+160.04%)
Lowest
$47.00 (+79.73%)
Analyst
Recommendation
Action
Price target
Projected
Date
Justin Walsh
JonesTrading
Buy
Reiterated
$82.00
+213.6%
11/12/2026
Joon Lee
UBS
Buy
Maintained
$64.00
+144.7%
11/05/2026
Delma Caiati
Guggenheim
Buy
Reiterated
$66.00
+152.4%
11/04/2026
Douglas Tsao
H.C. Wainwright
Buy
Reiterated
$63.00
+140.9%
11/05/2026
Benjamin Burnett
Wells Fargo
Buy
Reiterated
$47.00
+79.7%
11/05/2026
Salveen Richter
Goldman Sachs
Buy
Maintained
$68.00
+160%
10/21/2026
Jason Butler
Citizens JMP
Buy
Maintained
$91.00
+248%
10/20/2026
Tiago Fauth
Raymond James
Buy
Maintained
$86.00
+228.9%
10/20/2026
Rudy Li
Wolfe Research
Buy
Initiated
$50.00
+91.2%
10/15/2026
Unknown Analyst
Guggenheim
Buy
Initiated
$65.00
+148.6%
10/05/2026
Kambiz Yazdi
BTIG
Buy
Maintained
$75.00
+186.8%
10/01/2026
Myles Minter
William Blair
Buy
Maintained
-
-
09/23/2026
Danielle Brill
Truist Financial
Buy
Maintained
-
-
09/23/2026
Joseph Thome
TD Cowen
Buy
Maintained
-
-
09/22/2026
Paul Matteis
Stifel Nicolaus
Buy
Reiterated
$56.00
+114.1%
09/16/2026
Marc Goodman
Leerink Partners
Buy
Initiated
$52.00
+98.9%
06/24/2026
Unknown Analyst
Raymond James
Buy
Initiated
$66.00
+152.4%
04/09/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
-
20.00M
-
-
Cost of goods sold
-
32.72M
51.41M
31.35M
Cost of revenue
-
32.72M
51.41M
31.35M
Research and development expenses
30.26M
-
-
2.97M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
8.25M
11.50M
9.39M
9.77M
Operating expense
38.51M
11.50M
9.39M
12.74M
Total operating expenses
38.51M
44.22M
60.81M
44.09M
Operating income
-38.51M
-24.22M
-60.81M
-44.09M
Other non operating income
-
-
-
-
EBT including unusual items
-33.76M
-19.86M
-56.62M
-40.24M
EBT excluding unusual items
-33.76M
-19.86M
-56.62M
-40.24M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-33.76M
-19.86M
-56.62M
-40.24M
Net profit margin
-
-99.28%
-
-
Earnings per share
-0.72
-0.42
-1.19
-0.84
Interest and investment income
4.75M
4.36M
4.19M
3.85M
Interest expense
-
-
-
-
Net interest expenses
4.75M
4.36M
4.19M
3.85M
Depreciation and amortization charges
-
-
-
-
EBITDA
-38.24M
-23.99M
-60.59M
-43.89M
Gain or loss from assets sale
-
153.00K
-1.00K
-15.00K
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google apps